# Evolocumab in STEMI

> **NCT06081803** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sejong General Hospital** · enrollment: 166 (estimated)

## Conditions studied

- ST Elevation Myocardial Infarction

## Interventions

- **DRUG:** Repatha®

## Key facts

- **NCT ID:** NCT06081803
- **Lead sponsor:** Sejong General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-05
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 166 (ESTIMATED)
- **Last updated:** 2025-06-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06081803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06081803, "Evolocumab in STEMI". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06081803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*